PRP stands for platelet-rich plasma. It is prepared from the patient's own blood. Depending on the preparation method, platelet concentration, leukocyte content, residual erythrocytes, anticoagulant, volume and possible activation can vary considerably.

Platelets contain biologically active molecules such as PDGF, TGF-β and VEGF. Numerous signalling molecules are released after activation. This makes platelet-based preparations biologically interesting – but it does not mean that every product derived from PRP has the same properties or the same clinical effect.

The research hypothesis is based less on the idea that concentrated platelets simply circulate throughout the body and more on the molecules released during platelet activation. These include growth factors, cytokines and other regulatory proteins.

Direct human literature on intravenous PRP or aaPRP is limited. The most important papers largely come from the same research environment and address different questions. That matters when interpreting the evidence: several publications do not automatically represent several independent confirmations.

The phase I/II study with ten patients is interesting as an early feasibility study. At the same time, the patients also received treatments including oxygen, dexamethasone, favipiravir, antibiotics and heparin. Without an appropriate comparison group, it is not possible to determine how much of the clinical course was attributable to aaPRP. [1]

The uncertainty is even clearer in the second pilot study with seven patients. Mean IL-1β decreased in the three patients classified as “severe”, while it increased in the four “critical” patients. Three of the four critically ill patients died. The PaO₂/FiO₂ ratio improved across all patients, whereas the Lung Injury Score did not improve significantly. [2]

A simple distinction between experimental data, small human studies and an actually established therapy helps to keep the current research status in perspective.

Click a topic to open the current assessment.

The largest published IV-aaPRP safety series included 611 patients and 4,244 administrations. The authors documented no aaPRP-related allergic reactions, infections or coagulation problems. This is a relevant observational signal, but not definitive proof of safety. [3]

“Autologous” or “from the patient's own blood” does not automatically mean risk-free either. Blood collection, open or closed processing, sterility, composition and route of administration are separate safety factors.

Even in the much better studied field of local PRP applications, comparison between studies is limited. A systematic review of 75 randomised trials involving 5,726 participants found substantial differences in preparation and use. [6]

Another systematic analysis of 124 studies in musculoskeletal PRP research found that only 15 studies – 12.1% – described the preparation protocol clearly enough to be reproducible; only 26.6% quantified the composition of the final PRP product. [7]

In the literature evaluated for this article up to 01 September 2026, there is still no broad series of high-quality, independently replicated randomised trials confirming IV-PRP as an established systemic therapy for neurological, autoimmune, chronic inflammatory or anti-ageing indications.

Scientifically, the focus may increasingly shift away from the broad label “PRP” towards more precisely defined platelet-based products. These include platelet releasates, lysates or other cell-free fractions. In principle, such preparations can be characterised more precisely than an unspecifically labelled PRP product.

This does not mean that clinical benefit from such systemic applications has already been established. Rather, it describes a possible direction for research: away from an imprecise product label and towards clearly defined composition, dose, pharmacokinetics and clinical endpoints.